← Back to dashboard
Stryker
Stryker's Mako franchise makes it one of the clearest scaled robotics names in orthopedics.
Metric timing
This page mixes live market data, trailing fundamentals, and latest reported statement data.
Live / market snapshot
Price, 1D change, market cap, and enterprise value are current market-based figures.
TTM / forward
Most valuation and margin cards are trailing twelve months, while forward P/E uses forward consensus.
Latest quarter / dividend cadence
Balance-sheet ratios use the latest reported quarter. Dividend cadence is inferred from recent payout history.
latest annual revenue
latest quarterly revenue
latest annual profit
latest quarterly profit
annualized per share
latest ex-dividend cash amount
Latest headlines
Recent company headlines. Each link opens the original article in a new tab.
Stryker (SYK) Foot And Ankle Push Keeps Undervalued Narrative In Focus
Why Stryker’s new Foot & Ankle push matters for shareholders Stryker (SYK) is putting fresh attention on its Foot & Ankle franchise, rolling out new planning tools and limb reconstruction hardware at the 2026 AOFAS meeting in Seattle. The spotlight is on Prophecy Surgical Planning, now linked to the Incompass Total Ankle System, and on the Hoffmann LRF smartHEX platform, which extends the company’s reach into complex deformity correction supported by mobile software. Set against this product...
How Far Can BSX Stock Swing After Losing More Than Half Its Value?Boston Scientific (BSX) stock has fallen 55.5% over the past twelve months, and at $43.72 it trades barely above its 52-week low of $42.63. The options market now prices a likely one-year range from $28.46 to $67.16 a share. That band is wide, but it is close to how much the stock has already been moving.
Stryker (SYK) Expanded Its Foot And Ankle PortfolioStryker (NYSE:SYK) announced new Foot & Ankle portfolio updates, including expanded Prophecy Surgical Planning, at a major industry meeting. The company introduced the Hoffmann LRF smartHEX system, aimed at limb reconstruction and patient connectivity in complex cases. Expanded planning tools and patient specific technologies are intended to support surgeon decision making in ankle replacement procedures. The Prophecy Surgical Planning expansion and Hoffmann LRF smartHEX launch sit alongside...
3 Defensive Dividend Stocks For Steady Income as Fed Pressure BuildsMarkets are wrestling with a Fed that sounds more willing to tolerate economic pain than investors expected, while supply shocks from oil and tariffs keep pressure on costs. That mix tends to push attention toward reliable cash flows and dividends, as many traders reassess how much risk they really want to hold. This article walks through three large-cap, income-focused stocks exposed to this macro backdrop and explains how each may factor into your portfolio decisions now. The stocks below...
Ambulatory Surgery Centers Are Becoming ISRG's New Growth EngineIntuitive Surgical is expanding robotic surgery in ASCs with lower-cost XiR systems, opening access to new customers and outpatient procedures.
How Far Could ISRG Stock Bounce From Here?Intuitive Surgical (ISRG) stock could climb 23.9% to the April high it last fell back from, and you would risk about 5% to find out. That looks like a surgical-robot leader on sale, but the price history disagrees. Over the last two years, none of its visits to this price range turned into a 20% gain before a 5% drop.
Why it could benefit going forward
- Stryker's Mako franchise makes it one of the clearest scaled robotics names in orthopedics.
- Recent expansion into handheld robotics broadens the Mako platform and gives the sleeve another real medical-robotics leader.
- It adds exposure to hospital robotics without relying on the exact same thesis as Intuitive.
Moat / edge
- Established Mako installed base and surgeon workflow integration.
- Strong orthopedic distribution and clinical relationships.
- A robotics platform that can expand across procedures over time.
What to watch
- Mako placements and utilization.
- Adoption of new handheld robotics offerings.
- How much robotics continues to differentiate Stryker in orthopedics.
Key risks
- Hospital budgets and elective procedure trends can affect demand.
- The robotics narrative is important, but it still sits inside a broader medtech company.
Business snapshot
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.